Management of infantile subglottic hemangioma: acebutolol or propranolol?
The successful management of subglottic hemangioma with propranolol has been reported. We report three cases of subglottic hemangioma treated with the cardioselective beta-blocker acebutolol, 8 mg/kg/day. Treatment was efficient in two cases while an open procedure was necessary in the third child. In our experience, acebutolol could be easily administered in oral form twice-a-day only with a dose that was adaptable according to the growth of the child and showed no side effects. We also report a case of rebound growth after beta-mimetic drug use and the efficiency of propranolol treatment in such a recurrence. Considering the lack of side effects and the advantages in terms of administration, we suggest acebutolol as a first-line treatment of subglottic hemangiomas for which intervention is required.
Blanchet
Catherine
C
ENT Department, CHU Montpellier, France.
Nicollas
Richard
R
Bigorre
Michèle
M
Amedro
Pascal
P
Mondain
Michel
M
D000070:Acebutolol / Q000008:administration & dosage*; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005931:Glottis / Q000473:pathology; D006391:Hemangioma / Q000151:congenital / Q000188:drug therapy*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000151:congenital / Q000188:drug therapy* / Q000601:surgery; D007828:Laryngoscopy / Q000379:methods; D007829:Laryngostenosis / Q000175:diagnosis / Q000209:etiology; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000601:surgery*; D011433:Propranolol / Q000008:administration & dosage*; D012494:Sampling Studies; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000070:Acebutolol; D011433:Propranolol